Truist Securities Reiterates Buy on ANI Pharmaceuticals, Maintains $70 Price Target
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Gregory Fraser has reiterated a 'Buy' rating on ANI Pharmaceuticals (NASDAQ:ANIP) and maintained a price target of $70.
August 21, 2023 | 1:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ANI Pharmaceuticals' stock rating has been reiterated as 'Buy' by Truist Securities with a maintained price target of $70.
The reiteration of a 'Buy' rating by a reputable analyst like Gregory Fraser from Truist Securities is a positive signal for ANI Pharmaceuticals. The maintained price target of $70 indicates that the analyst believes the stock has potential for growth, which could attract investors and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100